Literature DB >> 33715181

Teledermatology in times of COVID-19.

Pia-Charlotte Stadler1, Sonja Senner1, Surina Frey1, Benjamin M Clanner-Engelshofen1, Leonie H Frommherz1, Lars E French1,2, Markus Reinholz1.   

Abstract

Remote consultations are likely to grow in importance in the following years, especially if the coronavirus disease 2019 (COVID-19) pandemic continues. Patients' opinions on teledermatology have already been analyzed, but a current analysis during the COVID-19 pandemic is lacking. The purpose of this survey was to investigate the satisfaction of patients who had received dermatological advice via telephone during the COVID-19 pandemic and to analyze their general opinion about eHealth as well as possible limitations for a broad implementation. Ninety-one patients managed in the dermatology department using telephone consultation during the COVID-19 pandemic were interviewed. An anonymous questionnaire, including the established quality of life questionnaire (Dermatology Life Quality Index [DLQI]), was used. It was found that men were more satisfied with telephone consultations than women (p = 0.029), educational level and age did not correlate with satisfaction (p = 0.186 and 388, respectively), and the longer the waiting time for a telephone consultation, the lower the satisfaction (p = 0.001). Grouped analysis of all participants showed that the majority (54.0% n = 38/71) were "very happy" with the telephone consultation. Higher disease burden (DLQI) was associated with lower satisfaction (p = 0.042). The main stated reasons for using telemedicine were shorter waiting times (51.6% n = 47/91) and no travel requirement (57.1% n = 47/91). Almost one-quarter (23.1% n = 21/89) of patients would use teledermatology in the future, 17.6% (n = 16/89) would not, and 57.1% (n = 51/89) would only use it in addition to a traditional consultation with personal contact. In conclusion, most patients in the study group still preferred traditional face-to-face medical consultations to telephone consultations, but also desired an add-on telemedical tool. Dermatological care using more modern telemedicine technologies than telephone conferencing is needed to better address patients' desires, especially in times of the COVID-19 pandemic.
© 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.

Entities:  

Keywords:  barriers; coronavirus disease 2019 pandemic; eHealth; teledermatology; telemedicine

Year:  2021        PMID: 33715181     DOI: 10.1111/1346-8138.15812

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  5 in total

1.  Telemedicine Use by Oculoplastic Surgeons During the COVID-19 Pandemic.

Authors:  Gary J Lelli; Susan Luo; Yao Liu; Suzanne W van Landingham
Journal:  Telemed J E Health       Date:  2021-09-29       Impact factor: 5.033

2.  Using Implementation Science to Understand Teledermatology Implementation Early in the COVID-19 Pandemic: Cross-sectional Study.

Authors:  Shanelle Mariah Briggs; Jules Benjamin Lipoff; Sigrid Marie Collier
Journal:  JMIR Dermatol       Date:  2022-06-09

Review 3.  Teledermatology in the time of COVID-19.

Authors:  Ahmed Elsayed Ibrahim; Mayar Magdy; Eslam M Khalaf; Alshimaa Mostafa; Ahmed Arafa
Journal:  Int J Clin Pract       Date:  2021-11-04       Impact factor: 3.149

4.  Teledermatology to Facilitate Patient Care Transitions From Inpatient to Outpatient Dermatology: Mixed Methods Evaluation.

Authors:  Samantha M R Kling; Erika A Saliba-Gustafsson; Marcy Winget; Maria A Aleshin; Donn W Garvert; Alexis Amano; Cati G Brown-Johnson; Bernice Y Kwong; Ana Calugar; Ghida El-Banna; Jonathan G Shaw; Steven M Asch; Justin M Ko
Journal:  J Med Internet Res       Date:  2022-08-03       Impact factor: 7.076

Review 5.  Teledermatology versus Face-to-Face Dermatology: An Analysis of Cost-Effectiveness from Eight Studies from Europe and the United States.

Authors:  Remedios López-Liria; María Ángeles Valverde-Martínez; Antonio López-Villegas; Rafael Jesús Bautista-Mesa; Francisco Antonio Vega-Ramírez; Salvador Peiró; Cesar Leal-Costa
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.